Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.

Animals Nanogels Macaca mulatta Tissue Distribution Drug Delivery Systems Administration, Intranasal Pneumococcal Vaccines
Biodistribution Drug delivery system Mouse Nasal vaccine Non-human primate Positron emission tomography (PET)

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
31 07 2023
Historique:
received: 01 11 2022
revised: 14 06 2023
accepted: 19 06 2023
medline: 24 7 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Cationic cholesteryl-group-bearing pullulan nanogel (cCHP-nanogel) is an effective drug-delivery system for nasal vaccines. However, cCHP-nanogel-based nasal vaccines might access the central nervous system due to its close proximity via the olfactory bulb in the nasal cavity. Using real-time quantitative tracking of the nanogel-based nasal botulinum neurotoxin and pneumococcal vaccines, we previously confirmed the lack of deposition of vaccine antigen in the cerebrum or olfactory bulbs of mice and non-human primates (NHPs), rhesus macaques. Here, we used positron emission tomography to investigate the biodistribution of the drug-delivery system itself, cCHP-nanogel after mice and NHPs were nasally administered with

Identifiants

DOI: 10.1016/j.vaccine.2023.06.065 PMID: 37385890
pubmed: 37385890
pii: S0264-410X(23)00754-5
doi: 10.1016/j.vaccine.2023.06.065
pii:
doi:

Substances chimiques

polyethylene glycol polyethyleneimine nanogel 0
Nanogels 0
pullulan 8ZQ0AYU1TT
Pneumococcal Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4941-4949

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yoshikazu Yuki (Y)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; HanaVax Inc, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan. Electronic address: yukiy@ims.u-tokyo.ac.jp.

Norihiro Harada (N)

Central Research Laboratory, Hamamatsu Photonics K.K, Shizuoka, Japan.

Shin-Ichi Sawada (SI)

Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan; Future Mucosal Vaccine Research and Development Synergy Institute, Chiba University, Chiba, Japan.

Yohei Uchida (Y)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan.

Rika Nakahashi-Ouchida (R)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan; Future Mucosal Vaccine Research and Development Synergy Institute, Chiba University, Chiba, Japan.

Hiromi Mori (H)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan.

Tomoyuki Yamanoue (T)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan.

Tomonori Machita (T)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan.

Masakatsu Kanazawa (M)

Central Research Laboratory, Hamamatsu Photonics K.K, Shizuoka, Japan.

Dai Fukumoto (D)

Central Research Laboratory, Hamamatsu Photonics K.K, Shizuoka, Japan.

Hiroyuki Ohba (H)

Central Research Laboratory, Hamamatsu Photonics K.K, Shizuoka, Japan.

Takashi Miyazaki (T)

Toko Yakuhin Kogyo Co., Ltd, Japan.

Kazunari Akiyoshi (K)

Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan.

Kohtaro Fujihashi (K)

Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan; Future Mucosal Vaccine Research and Development Synergy Institute, Chiba University, Chiba, Japan; Division of Mucosal Vaccines, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatric Dentistry, The University of Alabama at Birmingham, Birmingham, AL, USA.

Hiroshi Kiyono (H)

Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; HanaVax Inc, Tokyo, Japan; Future Mucosal Vaccine Research and Development Synergy Institute, Chiba University, Chiba, Japan; Mucosal Immunology and Allergy Therapeutics, Institute for Global Prominent Research, Future Medicine Education and Research Organization, Chiba University, Chiba, Japan; CU-UCSD Center for Mucosal Immunology, Allergy, and Vaccine (cMAV) Division of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Biodistribution assessment of cationic...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Nanogels › Biodistribution assessment of cationic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Biodistribution assessment of cationic...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Biodistribution assessment of cationic...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Biodistribution assessment of cationic...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie topique › Administration par voie muqueuse › Administration par voie nasale › Biodistribution assessment of cationic...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antibactériens › Vaccins antistreptococciques › Vaccins antipneumococciques › Biodistribution assessment of cationic...